5.32Open5.32Pre Close0 Volume48 Open Interest22.50Strike Price0.00Turnover6578.70%IV1.38%PremiumJan 17, 2025Expiry Date5.08Intrinsic Value100Multiplier-2DDays to Expiry0.24Extrinsic Value100Contract SizeAmericanOptions Type-0.9260Delta0.0482Gamma3.38Leverage Ratio-83.8755Theta0.0000Rho-3.13Eff Leverage0.0001Vega
Grail Stock Discussion
Larger Image: tradingview.com...
$Grail (GRAL.US)$
GRAIL Advances the Galleri® Registrational Clinical Trial Program
GRAIL (NASDAQ: GRAL) has announced significant progress in its clinical trials for the Galleri® multi-cancer early detection (MCED) test. The company has completed enrollment of over 35,000 participants in the PATHFINDER 2 study across North America and finished the final study visits for the NHS-Galleri trial with more than 140,000 participants in England. Results from the first 25,000 PATHFINDER 2 participan...
No comment yet